SAN DIEGO — April 27, 2009 — AltheaDx, a world leader in the development of companion diagnostics and biopharma services, today announced the formation of their Scientific Advisory Board with the appointments of four preeminent scientists.
“We are delighted to have assembled such an accomplished group of scientific leaders as initial appointments to our Scientific Advisory Board,” said David Macdonald, CEO of AltheaDx. “As a group, this Board will provide solid scientific support for the AltheaDx strategy of bringing theranostics into clinical use. The Board’s collective experience will serve as a valuable resource as we continue to advance our pipeline of projects and develop exciting new diagnostic opportunities and alliances.”
+
Headlines
ALL NEWS
AltheaDx Forms Scientific Advisory Board
AltheaDx Expands Genotyping Menu for Drug Metabolism
SAN DIEGO — April 16, 2009 — AltheaDx announced today the launch of its Affymetrix Drug Metabolizing Enzymes & Transporter (DMET) genotyping microarray service. The new service provides biopharmaceutical clients with the world’s most comprehensive way to measure the genetics of drug metabolism in clinical trial patients—giving drug developers the opportunity to select patients that are more likely to respond.
AltheaDx will provide its customers with a report featuring a patient’s genetic data in an interpretable format that can be directly integrated into existing protocols. This is made possible by leveraging software tools to translate raw genetic data from each patient into a conventional star allele nomenclature (i.e., CYP2D6*5 or CYP2C19*2), with which biopharma project teams are familiar.
+
Clinical Researchers Get New Tool to Ensure Accuracy of Genetic Testing
SAN DIEGO — March 24, 2009 — AltheaDx announced today the launch of RNA QC, a new service that informs clinical researchers of the accuracy of results from a patient’s genetic test – for diagnosis, prognosis or prediction of therapeutic response. The test is the world’s first to examine the quality of RNA isolated from specimens that are preserved through formalin fixation and then paraffin embedded (FFPE), a process that severely degrades genetic material.
+
AltheaDx to Offer the DxS K-RAS Test for Clinical Studies
MANCHESTER, UK — November 4, 2008 — DxS Ltd, a personalised medicine company and leader in the provision of companion diagnostics, have today announced an agreement with US-based Oncology diagnostic and biopharmaceutical services company AltheaDx, Inc., which will provide US study centres with access to DxS’ K-RAS mutation detection assays.
+
